Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
2000 1
2002 1
2003 3
2004 3
2005 2
2006 2
2007 3
2009 1
2011 1
2012 6
2013 7
2014 9
2015 12
2016 5
2017 3
2018 7
2019 11
2020 14
2021 16
2022 13
Text availability
Article attribute
Article type
Publication date

Search Results

104 results
Results by year
Filters applied: . Clear all
Page 1
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Strati P, et al. Among authors: iyer sp. Blood. 2021 Jun 10;137(23):3272-3276. doi: 10.1182/blood.2020008865. Blood. 2021. PMID: 33534891 Free PMC article.
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Pinnix CC, et al. Among authors: iyer sp. Blood Adv. 2020 Jul 14;4(13):2871-2883. doi: 10.1182/bloodadvances.2020001837. Blood Adv. 2020. PMID: 32589728 Free PMC article.
CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.
Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. Greenbaum U, et al. Among authors: iyer sp. Blood Adv. 2021 Jul 27;5(14):2799-2806. doi: 10.1182/bloodadvances.2021004575. Blood Adv. 2021. PMID: 34264268 Free PMC article.
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Zhao S, et al. Among authors: iyer sp. Am J Hematol. 2020 Jun;95(6):623-629. doi: 10.1002/ajh.25796. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32239765 Free article. Clinical Trial.
Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2.
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen SLS, Zinzani PL, Truemper LH, Illidge TM, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer SP. Savage KJ, et al. Among authors: iyer sp. Blood Adv. 2022 Apr 25:bloodadvances.2020003971. doi: 10.1182/bloodadvances.2020003971. Online ahead of print. Blood Adv. 2022. PMID: 35470385
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M; Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Wang ML, et al. Among authors: iyer sp. Lancet Oncol. 2022 Mar;23(3):406-415. doi: 10.1016/S1470-2045(21)00638-0. Epub 2022 Jan 21. Lancet Oncol. 2022. PMID: 35074072 Clinical Trial.
Targeted based therapy in nodal T-cell lymphomas.
Chihara D, Miljkovic M, Iyer SP, Vega F. Chihara D, et al. Among authors: iyer sp. Leukemia. 2021 Apr;35(4):956-967. doi: 10.1038/s41375-021-01191-8. Epub 2021 Mar 4. Leukemia. 2021. PMID: 33664464 Review.
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Saini NY, et al. Among authors: iyer sp. Blood Cancer Discov. 2022 Sep 6;3(5):385-393. doi: 10.1158/2643-3230.BCD-21-0177. Blood Cancer Discov. 2022. PMID: 35533245
104 results